Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Laura Huppert, MD
University of California, San Francisco
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- O'Neal Comprehensive Cancer Center
Birmingham, Alabama, United States
- University of California, San Francisco
San Francisco, California, United States
- Georgetown University
Washington D.C., District of Columbia, United States
- University of Chicago Medicine Comprehensive Cancer Center
Evergreen Park, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Duke Cancer Institute
Durham, North Carolina, United States
- Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Vanderbilt University Ingram Cancer Center
Nashville, Tennessee, United States
- Baylor College of Medicine
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jul 2019
- Primary completion
- 31 Jan 2027
- Completion
- 31 Jan 2027
- Last update posted
- 17 Apr 2026
- Registered enrollment
- 145
- Registry id
- NCT03971409
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.